Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Meininger
Jeremy Shefner
Merit Cudkowicz

Showing results (11-20 of 292) with videos related to

Pageof 30
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
ALS drug development: reflections from the past and a way forwardSwati Aggarwal, Merit Cudkowicz
Expert Review of Neurotherapeutics|March 15, 2006
Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapiesLucie I Bruijn, Merit Cudkowicz
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 15, 2008
Design of phase II ALS clinical trialsDavid A Schoenfeld, Merit Cudkowicz
The Lancet. Neurology|April 6, 2010
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialSwati P Aggarwal, Lorne Zinman, Elizabeth Simpson, et al.
Current Opinion in Neurology|November 20, 2012
Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosisMatthew Gladman, Merit Cudkowicz, Lorne Zinman
Expert Review of Molecular Diagnostics|May 19, 2006
Biomarkers for amyotrophic lateral sclerosisRobert Bowser, Merit Cudkowicz, Rima Kaddurah-Daouk
Clinical Investigation|February 17, 2017
Outcome measures in amyotrophic lateral sclerosis clinical trialsSabrina Paganoni, Merit Cudkowicz, James D Berry
Expert Opinion on Investigational Drugs|November 27, 2009
Arimoclomol: a potential therapy under development for ALSVeena Lanka, Scott Wieland, Jack Barber, et al.
Muscle & Nerve|August 8, 2006
Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosisJeremy M Shefner, Merit Cudkowicz, Robert H Brown
Nature Aging|November 2, 2024
Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosisSabrina Paganoni, Brittney Harkey, Elisa Giacomelli, et al.
Pageof 30

Showing results (11-20 of 292) with videos related to

Sort By:
Pageof 30
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
ALS drug development: reflections from the past and a way forwardSwati Aggarwal, Merit Cudkowicz
Expert Review of Neurotherapeutics|March 15, 2006
Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapiesLucie I Bruijn, Merit Cudkowicz
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 15, 2008
Design of phase II ALS clinical trialsDavid A Schoenfeld, Merit Cudkowicz
The Lancet. Neurology|April 6, 2010
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialSwati P Aggarwal, Lorne Zinman, Elizabeth Simpson, et al.
Current Opinion in Neurology|November 20, 2012
Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosisMatthew Gladman, Merit Cudkowicz, Lorne Zinman
Expert Review of Molecular Diagnostics|May 19, 2006
Biomarkers for amyotrophic lateral sclerosisRobert Bowser, Merit Cudkowicz, Rima Kaddurah-Daouk
Clinical Investigation|February 17, 2017
Outcome measures in amyotrophic lateral sclerosis clinical trialsSabrina Paganoni, Merit Cudkowicz, James D Berry
Expert Opinion on Investigational Drugs|November 27, 2009
Arimoclomol: a potential therapy under development for ALSVeena Lanka, Scott Wieland, Jack Barber, et al.
Muscle & Nerve|August 8, 2006
Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosisJeremy M Shefner, Merit Cudkowicz, Robert H Brown
Nature Aging|November 2, 2024
Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosisSabrina Paganoni, Brittney Harkey, Elisa Giacomelli, et al.
Pageof 30